Leprosy Treatment Market Research Report- Forecast till 2027

Leprosy Treatment Market information: by drug class (sulfone, phenazine, derivative, anti-tubercular drugs, others), Disease type (paucibacillary leprosy, multibacillary leprosy), Market channel (private, contract, others) - Forecast till 2027

ID: MRFR/Pharma/2575-HCR | October 2022 | Region: Global | 110 Pages         

Leprosy Treatment Market Speak to Analyst Request a Free Sample

Leprosy Treatment Market Overview:


Leprosy is a chronic infection caused by the bacteria Mycobacterium leprae or Mycobacterium lepromatosis causing granulomas of the nerves, respiratory tract etc. The granulomas may result in lack of ability to feel pain, especially in the extremities such as finger tips. The leprosy treatment market is falling due to early detection and awareness campaigns and integration of basic leprosy services into general health services of many countries.


Considering all these factors the Leprosy treatment market is expected to reach USD 3.5 billion by the end of 2023, Leprosy treatment market is projected to growing at a CAGR of ~ 3.2% during 2017-2023.


Study objectives:



  • To provide a detailed analysis of the market structure along with estimated future growth forecast for the next six years about various segments and sub-segments of the leprosy treatment market.

  • To provide insights about factors affecting the leprosy treatment market growth.

  • To analyze the leprosy treatment market based on various factors - Price Analysis, Supply Chain Analysis, Porters Five Force analysis etc.

  • To provide past and estimated future revenue of the market’s segments and sub-segments with respect to four main geographies and their countries - the Americas, Europe, Asia Pacific along with Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future growth prospects.

  • To provide country level analysis of the market which includes segmentation by drug class, disease type and market channel.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape of the leprosy treatment market.

  • To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments that are currently taking place in the leprosy treatment markets.


Research methodology

 


Sources: World Health Organization (WHO), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centre for Health Informatics, India

Key players of Leprosy treatment Market:


Key players profiled in the report are Glaxo Smithcline, Systopic Laboratories Pvt. Ltd., Cadila Pharmaceuticals, Acme Pharmaceuticals, Macleods Pharmaceuticals, Novartis International AG, Astra Zeneca, Lark Laboratories Ltd., and others.`


Leprosy treatment Market Segments:


The leprosy treatment market is segmented on the basis of drug class, disease type and market channel. Based on drug class, the market has been segmented as sulfone, phenazine, derivative, anti-tubercular drugs and others. Based on the disease type, the leprosy treatment market has been segmented as paucibacillary leprosy, multibacillary leprosy. Based on the end users, the leprosy treatment market has been segmented as private, contract and others.


Figure 1  Leprosy treatment Market by Market Channel, 2016 (% Market Share)


 


 


Regional analysis


US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology in the US is also an important driver of the market for global leprosy treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.

The report for Leprosy treatment Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Intended Audience



  • Global Leprosy treatment market, manufacturers & suppliers

  • Research and development (R&D) companies

  • Market research and consulting service providers

  • Academic institutes and universities



Report Scope:

Report Attribute/Metric Details
  Market Size

  • 2023: USD 3.5 Billion
  • 2027: Significant Value
  •   CAGR   3.2% (2017-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Drug class, Disease type and Market channel
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Glaxo Smithcline, Systopic Laboratories Pvt. Ltd., Cadila Pharmaceuticals, Acme Pharmaceuticals, Macleods Pharmaceuticals, Novartis International AG, Astra Zeneca, Lark Laboratories Ltd., and others
      Key Market Opportunities

  • Rising government initiatives
  • Favourable reimbursement scenario for these treatments
  •   Key Market Drivers   Increasing prevalence of skin diseases


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The Valuation by 2023 Would be USD 3.5 Billion.

    The Projected CAGR For The Leprosy Treatment Would Be 3.2% During The Forecast Period Of 2017-2023.

    The Disease Type Includes Paucibacillary Leprosy And Multibacillary Leprosy.

    The Drug Types Are Phenazine, Sulfone, Anti-Tubercular Drugs, Derivative, And Others.

    The Players Are Systopic Laboratories Pvt. Ltd., GlaxoSmithKline, Acme Pharmaceuticals, Cadila Pharmaceuticals, Novartis International AG, Astra Zeneca, Macleods Pharmaceuticals, Lark Laboratories Ltd., and others.